Asensus Surgical (FRA:2TX) 3-Year EBITDA Growth Rate : 23.50% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Asensus Surgical 3-Year EBITDA Growth Rate?

Asensus Surgical's EBITDA per Share for the three months ended in Dec. 2023 was €-0.06.

During the past 3 years, the average EBITDA Per Share Growth Rate was 23.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 47.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 37.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Asensus Surgical was 73.00% per year. The lowest was -179.30% per year. And the median was 15.40% per year.

Competitive Comparison of Asensus Surgical's 3-Year EBITDA Growth Rate

For the Medical Devices subindustry, Asensus Surgical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Asensus Surgical's 3-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Asensus Surgical's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Asensus Surgical's 3-Year EBITDA Growth Rate falls into.

Asensus Surgical 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Asensus Surgical (FRA:2TX) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Asensus Surgical 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (FRA:2TX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (FRA:2TX) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ASXC:USA

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Asensus Surgical (FRA:2TX) Headlines

No Headlines